Nektar Presents 52-Week Alopecia Areata Trial Results
Nektar Therapeutics will host an investor conference call to unveil critical 52-week data from its REZOLVE-AA Phase 2b study examining rezpegaldesleukin as a potential treatment for alopecia areata. The biotech company’s presentation marks a significant milestone in the clinical development of this novel immunology therapy.
Nektar Presents 52-Week Alopecia Areata Trial Results Read More »










